Treatment of Castleman's disease

Current Treatment Options in Oncology

Volumn 6, Issue 3, 2005, Pages 255-266

  Dispenzieri, Angela ^a   Gertz, Morie A ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; CD20 ANTIBODY; CHLORAMBUCIL; CIDOFIVIR; CIMETIDINE; CLADRIBINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOSCARNET; GANCICLOVIR; HYALIN; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; PARACETAMOL; PREDNISONE; PROCARBAZINE; RITUXIMAB; THALIDOMIDE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ABDOMINAL DISCOMFORT; ACUTE LEUKEMIA; ACUTE PANCREATITIS; ALOPECIA; ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANGIONEUROTIC EDEMA; ANOREXIA; ASTHENIA; AUTOIMMUNE DISEASE; AVASCULAR NECROSIS; BEAM THERAPY; BONE MARROW SUPPRESSION; BONE PAIN; BRADYCARDIA; BRONCHOSPASM; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CLINICAL FEATURE; CONSTIPATION; COUGHING; CUSHING SYNDROME; CYTOPENIA; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG POTENTIATION; DYSPNEA; EDEMA; EYE DISEASE; FATIGUE; FEVER; FLU LIKE SYNDROME; HAND FOOT SYNDROME; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERHIDROSIS; HYPERTENSION; HYPERURICEMIA; HYPOTENSION; IMMUNOPATHOLOGY; INCIDENCE; INFECTION; INFERTILITY; INSOMNIA; INTERSTITIAL PNEUMONIA; IRRITABILITY; JAUNDICE; KAPOSI SARCOMA; LEUKOPENIA; LIVER TOXICITY; LUNG FIBROSIS; LUPUS ERYTHEMATOSUS; LYMPHADENOPATHY; LYMPHOCYTOPENIA; LYMPHOMA; MALAISE; MENTAL DISEASE; MOOD DISORDER; MOUTH ULCER; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NOMENCLATURE; OSTEOPOROSIS; PAIN; PATHOGENESIS; PEPTIC ULCER; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; PIGMENT DISORDER; PLASMA CELL; PLASMACYTOMA; PROGNOSIS; PRURITUS; RAYNAUD PHENOMENON; REVIEW; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; RHINITIS; RIGOR; SIDE EFFECT; SKIN CANCER; SKIN DISEASE; SOMNOLENCE; STOMATITIS; SYMPTOMATOLOGY; SYSTEMIC THERAPY; TACHYCARDIA; THROAT DISEASE; THROMBOCYTOPENIA; THROMBOSIS; THYROID DISEASE; URTICARIA; VASCULITIS; VOMITING; WISKOTT ALDRICH SYNDROME;

EID: 21744439539     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-005-0008-z     Document Type: Review

References (78)

1. Castleman B, Iverson L, Menendez VP: Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 1956, 9:822-830.
2. Frizzera G: Castleman's disease and related disorders. Semin Diagn Pathol 1988, 5:346-364.
3. Keller AR, Hochholzer L, Castleman B: Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972, 29:670-683.
4. Gaba AR, Stein RS, Sweet DL, et al.: Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978, 69:86-90.
5. Parez N, Bader-Meunier B, Roy CC, et al.: Paediatric Castleman's disease: report of seven cases and review of the literature. Eur J Pediatr 1999, 158:631-637.
6. Frizzera G, Banks PM, Massarelli G, et al.: A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am J Surg Pathol 1983, 7:211-231.
7. Menke DM, Camoriano JK, Banks PM: Angiofollicular lymph node hyperplasia: a comparison of unicentric, multicentric, hyaline vascular, and plasma cell types of disease by morphometric and clinical analysis. Mod Pathol 1992, 5:525-530.
8. Gili A, Ngan BY, Lester R: Castleman's disease associated with pemphigus vulgaris. J Am Acad Dermatol 1991, 25:955-959.
9. Wang L, Bu D, Yang Y, et al.: Castleman's tumours and production of autoantibody in paraneoplastic pemphigus. Lancet 2004, 363:525-531.
10. Strohal R, Tschachler E, Breyer S, et al.: Reactivation of Behcet's disease in the course of multicentric HHV8-positive Castleman's disease: long-term complete remission by a combined chemo/radiation and interferon-alpha therapy regimen. Br J Haematol 1998, 103:788-790.
11. Franco V, Aragona F, Rodolico V, et al.: Castleman's disease associated with hepatic amyloidosis. An immunohistochemical and ultrastructural study. Haematologica 1984, 69:556-567.
12. Perfetti V, Bellotti V, Maggi A, et al.: Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. Am J Hematol 1994, 46:189-193.
13. Ordi J, Grau JM, Junque A, et al.: Secondary (AA) amyloidosis associated with Castleman's disease. Report of two cases and review of the literature. Am J Clin Pathol 1993, 100:394-397.
14. Johkoh T, Muller NL, Ichikado K, et al.: Intrathoracic multicentric Castleman disease: CT findings in 12 patients. Radiology 1998, 209:477-481.
15. Fujimoto W, Kanehiro A, Kuwamoto-Hara K, et al.: Paraneoplastic pemphigus associated with Castleman's disease and asymptomatic bronchiolitis obliterans. Eur J Dermatol 2002, 12:355-359.
16. Chin AC, Stich D, White FV, et al.: Paraneoplastic pemphigus and bronchiolitis obliterans associated with a mediastinal mass: A rare case of Castleman's disease with respiratory failure requiring lung transplantation. J Pediatri Surg 2001, 36:E22.
17. Wolff H, Kunte C, Messer G, et al.: Paraneoplastic pemphigus with fatal pulmonary involvement in a woman with a mesenteric Castleman tumour. Br J Dermatol 1999, 140:313-316.
18. Seida A, Wada J, Morita Y, et al.: Multicentric Castleman's disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury? Am J Kidney Dis 2004, 43:3-9.
19. Miadonna A, Salmaso C, Palazzi P, et al.: Fibrillary glomerulonephritis in Castleman's disease. Leuk Lymphoma 1998, 28:429-435.
20. Lui SL, Chan KW, Li FK, et al.: Castleman's disease and mesangial proliferative glomerulonephritis: the role of interleukin-6. Nephron 1998, 78:323-327.
21. Oksenhendler E, Boulanger E, Galicier L, et al.: High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002, 99:2331-2336.
22. Larroche C, Cacoub P, Soulier J, et al.: Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol 2002, 69:119-126.
23. Chan AC, Chan KW, Chan JK, et al.: Development of follicular dendritic cell sarcoma in hyaline-vascular Castleman's disease of the nasopharynx: tracing its evolution by sequential biopsies. Histopathol 2001, 38:510-518.
24. Soulier J, Grollet L, Oksenhendler E, et al.: Molecular analysis of clonality in Castleman's disease. Blood 1995, 86:1131-1138.
25. Belec L, Mohamed AS, Authier FJ, et al.: Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman's disease. Blood 1999, 93(11):3643-3653.
26. Soulier J, Grollet L, Oksenhendler E, et al.: Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995, 86(4):1276-1280.
27. Leger-Ravet MB, Peuchmaur M, Devergne O, et al.: Interleukin-6 gene expression in Castleman's disease. Blood 1991, 78(11):2923-2930.
28. Nishimoto N, Sasai M, Shima Y, et al.: Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000, 95:56-61.
29. McCarty MJ, Vukelja SJ, Banks PM, et al.: Angiofollicular lymph node hyperplasia (Castleman's disease). Cancer Treat Rev 1995, 21:291-310.
30. Frizzera G, Peterson BA, Bayrd ED, et al.: A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985, 3:1202-1216.
31. Chronowski GM, Ha CS, Wilder RB, et al.: Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001, 92:670-676.
32. Herrada J, Cabanillas F, Rice L, et al.: The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998, 128:657-662.
33. Kasantikul V, Panyavoravut V, Benjavongkulchai S, et al.: Castleman's disease: a clinicopathologic study of 12 cases. J Med Assoc Thai 1997, 80:195-201.
34. Smir BN, Greiner TC, Weisenburger DD: Multicentric angiofollicular lymph node hyperplasia in children: a clinicopathologic study of eight patients. Mod Pathol 1996, 9:1135-1142.
35. Oksenhendler E, Duarte M, Soulier J, et al.: Multicentric Castleman's disease in HTV infection: a clinical and pathological study of 20 patients. AIDS 1996, 10:61-67.
36. Weisenburger DD, Nathwani BN, Winberg CD, et al.: Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 1985, 16:162-172.
37. Loi S, Goldstein D, Clezy K, et al.: Castleman's disease and HIV infection in Australia. HIV Medicine 2004, 5:157-162.
38. Safford SD, Lagoo AS, Mahaffey SA: Preoperative embolization as an adjunct to the operative management of mediastinal Castleman disease. J Pediatr Surg 2003, 38:21-23.
39. Barbounis V, Efremidis A: A plasma cell variant of Castleman's disease treated successfully with cimetidine. Case report and review of the literature. Anticancer Res 1996, 16:545-547.
40. Repetto L, Jaiprakash MP, Selby PJ, et al.: Aggressive angiofollicular lymph node hyperplasia (Castleman's disease) treated with high-dose melphalan and autologous bone marrow transplantation. Hematol Oncol 1986, 4:213-217.
41. Dispenzieri A, Moreno-Aspitia A, Suarez GA, et al.: Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 2004, 104:3400-3407.
42. Advani R, Warnke R, Rosenberg S: Treatment of multicentric Castleman's disease complicated by the development of non-Hodgkin's lymphoma with high-dose chemotherapy and autologous peripheral stem-cell support. Ann Oncol 1999, 10:1207-1209.
43. Pavlidis NA, Skopouli FN, Bai MC, et al.: A successfully treated case of multicentric angiofollicular hyperplasia with oral chemotherapy (Castleman's disease). Med Pediatr Oncol 1990, 18:333-335.
44. Hudnall SD, Chen T, Brown K, et al.: Human herpesvirus-8-positive microvenular hemangioma in POEMS syndrome. Arch Pathol Lab Med 2003, 127:1034-1036.
45. Abdou S, Salib H: An extra ordinary respone of Castleman's disease to rituximab. Blood 2004, 104:49b.
46. Corbellino M, Bestetti G, Scalamogna C, et al.: Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001, 98:3473-3475.
47. Marcelin AG, Aaron L, Mateus C, et al.: Rituximab therapy for HIV-associated Castleman disease. Blood 2003, 102:2786-2788.
48. Marietta M, Pozzi S, Luppi M, et al.: Acquired haemophilia in HIV-negative, HHV-8-positive multicentric Castleman's disease: a case report. Eur J Haematol 2003, 70:181-182.
49. Lee FC, Merchant SH: Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. Am J Hematol 2003, 73:48-53.
50. Jung CP, Emmerich B, Goebel FD, et al.: Successful treatment of a patient with HIV-associated multicentric Castleman's disease (MCD) with thalidomide. Am J Hematol 2004, 75:176-177.
51. Kumari P, Schechter GP, Saini N, et al.: Successful treatment of human immunodeficiency virus-related Castleman's disease with interferon-α. Clin Infect Dis 2000, 31:602-604.
52. Nord JA, Karter D: Low-dose interferon-α therapy for HIV-associated multicentric Castleman's disease. Int J STD AIDS 2003, 14:61-62.
53. Andres E, Maloisel F: Interferon-α as first-line therapy for treatment of multicentric Castleman's disease. Ann Oncol 2000, 11:1613-1614.
54. Pavlidis NA, Briassoulis E, Klouvas G, et al.: Is interferon-α an active agent in Castleman's disease? Ann Oncol 1992, 3:85-86.
55. Tamayo M, Gonzalez C, Majado MJ, et al.: Long-term complete remission after interferon treatment in a case of multicentric Castelman's disease. Am J Hematol 1995, 49:359-360.
56. Colleoni GW, Duarte LC, Kerbauy FR, et al.: 2-Chlorodeoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to non-Hodgkin's lymphoma. Acta Oncol 2003, 42:784-787.
57. Bordeleau L, Bredeson C, Markman S: 2-Chloro-deoxyadenosine therapy for giant lymph node hyperplasia. Br J Haematol 1995, 91:668-670.
58. Scott D, Cabral L, Harrington WJ, Jr.: Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. Am J Hematol 2001, 66:148-150.
59. Aaron L, Lidove O, Yousry C, et al.: Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin Infect Dis 2002, 35:880-882.
60. Beck JT, Hsu SM, Wijdenes J, et al.: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994, 330:602-605.
61. van Rhee F, Alikhan M, Munshi N, et al.: Anti-IL6 antibody (abs)-based strategies improve the management of HIV-negative Castleman's disease. Blood 2004, 104:897a.
62. Bowne WB, Lewis JJ, Filippa DA, et al.: The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999, 85:706-717.
63. Caneppele S, Picart N, Bayle-Lebey P, et al.: Paraneoplastic pemphigus associated with Castleman's tumour. Clin Exp Dermatol 2000, 25:219-221.
64. Ruggieri G, Barsotti P, Coppola G, et al.: Membranous nephropathy associated with giant lymph node hyperplasia. A case report with histological and ultrastructural studies. Am J Nephrol 1990, 10:323-328.
65. Mandreoli M, Casanova S, Vianelli N, et al.: Remission of nephrotic syndrome due to AA amyloidosis and initiation of glomerular repair after surgical resection of localized Castleman's disease. Nephron 2002, 90:336-340.
66. Lachmann HJ, Gilbertson JA, Gillmore JD, et al.: Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. QJM 2002, 95:211-218.
67. Gulati P, Sun NC, Herman BK, et al.: Isolated leptomeningeal Castleman's disease with viral particles in the follicular dendritic cells. Arch Pathol Lab Med 1998, 122:1026-1029.
68. Yamasaki S, Iino T, Nakamura M, et al.: Detection of human herpesvirus-8 in peripheral blood mononuclear cells from adult Japanese patients with multicentric Castleman's disease. Br J Haematol 2003, 120:471-477.
69. Chan TM, Cheng IK, Wong KL, et al.: Resolution of membranoproliferative glomerulonephritis complicating angiofollicular lymph node hyperplasia (Castleman's disease). Nephron 1993, 65:628-632.
70. Hattori K, Irie S, Isobe Y, et al.: Multicentric Castleman's disease associated with renal amyloidosis and pure red cell aplasia. Ann Hematol 1998, 77:179-181.
71. Liberato NL, Bollati P, Chiofalo F, et al.: Autoimmune hemolytic anemia in multicentric Castleman's disease. Haematologica 1996, 81:40-43.
72. Higashi K, Matsuki Y, Hidaka T, et al.: Primary Sjogren's syndrome associated with hyaline-vascular type of Castleman's disease and autoimmune idiopathic thrombocytopenia. Scand J Rheumatol 1997, 26:482-484.
73. Dispenzieri A, Kyle RA, Lacy MQ, et al.: POEMS syndrome: definitions and long-term outcome. Blood 2003, 101:2496-2506.
74. Rywlin AM, Rosen L, Cabello B: Coexistence of Castleman's disease and Kaposi's sarcoma. Report of a case and a speculation. Am J Dermatopathol 1983, 5:277-281.
75. Gerald W, Kostianovsky M, Rosai J: Development of vascular neoplasia in Castleman's disease. Report of seven cases. Am J Surg Pathol 1990, 14:603-614.
76. Suwannaroj S, Elkins SL, McMurray RW: Systemic lupus erythematosus and Castleman's disease. J Rheumatol 1999, 26:1400-1403.
77. Massey GV, Kornstein MJ, Wahl D, et al.: Angiofollicular lymph node hyperplasia (Castleman's disease) in an adolescent female. Clinical and immunologic findings. Cancer 1991, 68:1365-1372.
78. Crump JA, Beard ME, Angus HB, et al.: Acute adrenal insufficiency: a new presentation of Castleman's disease. J Intern Med 1995, 238:81-84.